

Evidence Discussion (ONC 27.10)

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma

Initial Staging

NCCN supports contrasted CT of chest, abdomen, and pelvis (Kumar 2024, Dimopoulous 2019). PET/ CT fusion is recommended equally with diagnostic CT by the NCCN, however the role of PET has not been definitively shown and is not used for treatment stratification at this time (Thomas 2019, Banwait 2011). Given the increased radiation exposure and cost of PET/CT without a clear benefit, PET/CT is not indicated for initial staging, restaging, or surveillance of lymphoplasmacytic lymphoma.

Restaging

NCCN supports contrasted, diagnostic quality CTs every 2 cycles of chemotherapy and at end of treatment to determine response and prevent under-treatment. Diagnostic, contrasted CTs of chest, abdomen, pelvis and previously involved areas are supported for suspected recurrence (Kumar 2024, Dimopoulous 2019). PET/CT is not consistently correlated with monoclonal protein response, which is the primary means of monitoring this entity and PET/CT is not recommended for restaging of this entity (Banwait 2011, Thomas 2019, Kumar 2024).

Surveillance

Surveillance of lymphoplasmacytic lymphoma is based on laboratory monitoring of blood counts and chemistries, serum proteins, and immunoglobulins. There is no established role for imaging surveillance in this entity (Thomas 2019, Kumar 2024).

References

1. Kumar SK, Elsedawy N, Martin T, et al. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 2.2024- December 5, 2023. All rights reserved. Accessed [April 30, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org.
2. Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. *Am J Hematol*. 2011 Jul;86(7):567-72. doi: 10.1002/ajh.22044. PMID: 21681781.
3. Thomas R, Braschi-Amirfarzan M, Laferriere SL, Jagannathan JP. Imaging of Waldenström Macroglobulinemia: A Comprehensive Review for the Radiologist in the Era of Personalized Medicine. *AJR Am J Roentgenol*. 2019 Dec;213(6):W248-W256. doi: 10.2214/AJR.19.21493. Epub 2019 Jul 9. PMID: 31287727.

4. Dimopoulos MA, Kastiris E. How I treat Waldenström macroglobulinemia. *Blood*. 2019 Dec 5;134(23):2022-2035. doi: 10.1182/blood.2019000725. PMID: 31527073.